What is the proposed neurocircuitry that underlies attention deficit hyperactivity disorder, or ADHD? What is known about the role of serotonin in ADHD? Particularly the 5HT2C and 5HT7 receptors?

With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD).

Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of ADHD and where the future lies.

Let’s listen in to Part 1 of our theme: Shifting Focus: A Novel Perspective on Attention Deficit Hyperactivity Disorder (ADHD)

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Jonathan Meyer addresses your unanswered questions from his presentation: Dopamine Partial Agonists: How They Work and Why They Don’t Always Play Nice with Other Antipsychotics.

In this episode, Dr. Jade Wu addresses your unanswered questions from her presentation: Goodnight Mom: Sleep Issues During Pregnancy and Postpartum.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation: The “Mania” Event: Distinguishing Between Treating Bipolar I and Bipolar II.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation “ADHD: Optimizing Treatment with Patient-Centered Care 

In this episode, Dr. Thomas Schwartz addresses your unanswered questions from his presentation “Can You Say Hey? The Many Faces of Serotonin 5HT2A” by Dr. Thomas Schwartz 

What is Match Day? What types of resources does Inside the Match provide for match applicants? In this episode, psychiatry resident, Dr. Simone Bernstein addresses these questions and much more!

Simone Bernstein is a fourth-year psychiatry resident at Washington University in St. Louis and Co-Founder of Inside the Match, a platform that provides free application and interview guidance to residency applicants as well as tips to be successful in residency. The platform has a website with 250+ blogs to help you prepare for the match and more than 120+ episodes on Spotify, Apple, and Google podcasts. Simone has spoken at conferences worldwide, is a Laughlin Fellow, Forbes 30 Under 30 Social Entrepreneur, was featured as one of Glamour Magazine’s Top 10 College Women, is an inductee in the Missouri Public Affairs Hall of Fame, and is also a Fulbright Scholar. Find Inside The Match on Instagram and Twitter @Inside_TheMatch. 

What sorts of imaging techniques are used to measure amyloid aggregates in the brain? What do we know about the relationship between symptoms of Alzheimer’s disease and amyloid levels that are detected through neuroimaging?

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.

Today, Dr. Andy Cutler interviews Dr. Lon Schneider on biomarkers for Alzheimer’s disease and treatments that target amyloid.

Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease.

Let’s listen in to Part 2 of our theme: Biomarkers and Treatments that Target Amyloid

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What cultural perspectives may influence mental health stigma in the Middle East? What was your experience like creating the first transcranial magnetic stimulation (TMS) center in Kuwait? What advice do you have for clinicians who want to help reduce the stigma that surrounds mental health?

In this episode, psychiatrist Dr. Mohammad Alsuwaidan address these questions and much more.

Dr. Mohammad Alsuwaidan MD, MPH, FRCPC, DipABPN is an assistant professor of psychiatry at the University of Toronto in Canada. He is also the founder and clinical director of MindWell, a leading regional private mental health center based in Kuwait and the Chief Medical Officer of TMS NextGen a TMS training and operations management company based in Dubai.

Dr. Alsuwaidan completed his psychiatry residency, mood & anxiety disorders fellowship and medical education fellowship at the University of Toronto. He also trained in mood disorders at the Stanford University bipolar clinic and the Tufts Medical Center mood disorders clinic. He completed a Masters of Public Health (MPH) at Johns Hopkins University.

He is a Fellow of the Royal College of Physicians and Surgeons of Canada, a Diplomate of the American Board of Psychiatry and Neurology and is certified in public health by the National Board of Public Health Examiners.

He was the host for the 2022 NEI Congress, and he is widely-sought internationally as a speaker, educator and anti-stigma advocate in mental health.

When it comes to Alzheimer’s disease, what is the amyloid cascade hypothesis? How has this theory impacted drug development for Alzheimer’s disease over the past three decades?

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.

Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of Alzheimer’s disease and the amyloid controversy.

Let’s listen in to Part 1 of our theme: Alzheimer’s Disease and the Amyloid Controversy

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we invite Dr. Christine Moutier of the American Foundation for Suicide Prevention, along with Christopher Thomas and Martha Thomas of the Defensive Line so they could have a chance to address some of your unanswered questions from their presentation on suicide prevention at the 2022 NEI Congress titled “Reasons to Hope: Evidence-Based Actions for Suicide Prevention.

Christine Moutier serves as the chief medical officer for the American Foundation for Suicide Prevention (AFSP) and knows the impact of suicide firsthand. After her own lived experience and losing physician colleagues to suicide, she dedicated herself to fighting this leading cause of death. For the past decade as CMO at AFSP, Dr. Moutier has been leading a nationwide movement fueled by science and grassroots. She has testified before Congress numerous times, presented at the White House and the National Academy of Sciences, and is a frequent expert contributor for major media outlets.  

Martha co-founded The Defensive Line with Chris and her son, Solomon to honor her daughter, Ella, and to bring a message of hope and help to other at-risk young people. She is the roots of her family and believes and demonstrates fundamentally that connection is our greatest source of strength. She recently stepped out of the classroom to work full-time in her role as the Chief Education Officer for the organization. While she is no longer in the classroom, she is still teaching others important lifesaving skills. As a teacher and educator for 30 years, Martha brings a deep understanding of the profession to The Defensive Line. Martha resides in Coppell, Texas with her husband, Chris, and two rescue dogs Mickey and Rebel. She is a marathoner and devoted friend to many, as well as a huge fan of the New York Jets for whom her son, Solomon, plays as a defensive lineman.

As a senior executive at Procter & Gamble, Frito-Lay, and Alberto Culver among others, Chris brought a drive for excellence to his work, earning recognition and industry awards including Salesperson of the Year and Supplier of the Year. He is a member of the Board of Directors of the American Foundation for Suicide Prevention, as well as Touched By Suicide (TBS) board member, AFSP Project 2025 board member, and College of Wooster Ad Hoc Alumni Trustee. Martha, Chris, and Solomon were recipients of the 2019 AFSP Lifesaver Award. During his 30-plus years in corporate management of consumer goods and products, both domestically and internationally. A gifted college athlete, Chris played an integral role in coaching and developing the athletic achievements of his children, Ella and Solomon.

In addition to receiving the AFSP Lifesaver Award in 2019 with Solomon, Martha and Chris are active with suicide survivors organizations, have spoken at the 2022 Neuroscience Education Institute Congress, Texas Association of Gifted and Talented Conference, United Healthcare Suicide Prevention Town Hall and many others.

Why is measurement-based care so important to the overall treatment of schizophrenia? What are the most important reasons for using plasma antipsychotic levels when treating schizophrenia patients?  

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the importance of measuring plasma levels when administering antipsychotics.  

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on complex treatment-resistant psychotic disorders. 

Episodes to be released under this theme include: 

• Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings 
• Part 2: The Clozapine Handbook with Dr. Jonathan Meyer 
• Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer 

Subscribe to the NEI Podcast, so that you don’t miss another episode! 

What did we learn about the relationship between PTSD and the gut microbiome this year? What are pherines? How can they reduce anxiety, according to research that was published this year? What other exciting news about psychopharmacology do you have to share with us? In this episode, Dr. Cutler addresses these questions and so much more about this past year in psychopharmacology.

Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996.

Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Why is clozapine underutilized, even though it’s a very effective antipsychotic for treatment-resistant schizophrenia? What led you to write The Clozapine Handbook?

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the use of clozapine in clinical practice. 

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings

Part 2: The Clozapine Handbook with Dr. Jonathan Meyer

Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Mary Kimmel answers your important questions from her presentation: No Woman, No Cry: Advancements in the Diagnosis and Treatment of Postpartum Depression.

In this episode, Dr. Napoleon Higgins answers your important questions from his presentation, To the Moon and Back: Pediatric ADHD.

In this episode, Dr. Andy Cutler addresses your unanswered questions from his presentation, New Kids on the Block: Novel Receptor Science in the Treatment of Major Depressive Disorder.

In this episode, Dr. Jeffrey Strawn answers your most pressing questions from his presentation, Blue Genes: Using Pharmacogenetics to Guide Prescribing.

In this episode, Dr. Adelaide Robb addresses your unanswered questions from her presentation: Assessment and Treatment of Pediatric Impulsive Aggression: A Transdiagnostic Issue.

What are the early diagnostic stages of Alzheimer’s disease? What sort of brain changes can occur up to 20 years prior to symptoms of Alzheimer’s disease?

In this episode, Dr. Danielle Goldfarb addresses these questions and much more! She shares the most current research on dementia and geriatrics relevant to clinical practice. She also shares resources for early diagnosis of dementia and treating mental health in geriatrics.

Dr. Danielle Goldfarb is an Assistant Professor of Neurology and Psychiatry at the University of Arizona and a dual board-certified neurologist and psychiatrist at the Banner Sun Health Research Institute and Cleo Roberts Memory Center in Sun City, AZ.  Dr. Goldfarb cares for patients and families with Alzheimer’s disease and related dementias (ADRD). She leads several Alzheimer’s clinical trials and is involved in research efforts to explore the neuropathologic substrates of early neuropsychiatric symptoms in ADRD, to improve the safety and efficiency of  the collection of cerebrospinal fluid biomarkers in older adults, and to expand access to ADRD care and research by underserved communities.

What made you both want to write the book “Management of Complex Treatment-Resistant Psychotic Disorders? What are some of the most challenging components to treat, when it comes to complex psychosis and how are these addressed in the book?

In this episode, Dr. Andrew Cutler interviews Dr. Michael Cummings on how to manage complex treatment-resistant psychotic disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings

Part 2: The Clozapine Handbook with Dr. Jonathan Meyer

Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are some of the major differences between intravenous or IV ketamine and intranasal esketamine? How are you building on these research findings and what associated avenues have been explored?

In this episode, we interview the poster winner from last year’s NEI Congress, Dr. Balwinder Singh on his research comparing intravenous ketamine and intranasal esketamine. The study, conducted at Mayo Clinic rendered interesting findings that may be important for clinicians.

Dr. Balwinder Singh is a Consultant and Assistant professor in the Department of Psychiatry at Mayo Clinic in Rochester, Minnesota. He is a psychiatrist specializing in mood disorders, and his research is focused on novel treatments for treatment-resistant depression and identifying biomarkers for ketamine response.  He is also involved in the ketamine and esketamine clinic practice at the Mayo Clinic Depression Center.  

This is one of the first studies to highlight a faster response to intravenous ketamine as compared to intranasal esketamine in an observational study.

Title: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study Byline: Balwinder Singh; Simon Kung; Vanessa Pazdernik; Kathryn M. Schak; Jennifer Geske; Phillip J. Schulte; Mark A. Frye; Jennifer L. Vande Voort Citation: J Clin Psychiatry 2023;84(2):22m14548 DOI: https://doi.org/10.4088/JCP.22m14548 URL: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study | Psychiatrist.com

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD.

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe novel mechanisms of action of agents under investigation for the treatment of depression
• Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression
• Integrate newly available options for depression into clinical practice

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types. The following are being offered for this activity:

• Nurse Practitioner: ANCC contact hours
• Pharmacy: ACPE application-based contact hours
• Physician: ACCME AMA PRA Category 1 Credits ™
• Physician Assistant: AAPA Category 1 CME credits
• Psychology: APA CE credits
• Social Work: ASWB-ACE CE credits
• Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.

Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee Vladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda

Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.

Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc.

Released: September 26, 2022     CME/CE credit expires: September 26, 2025

Description: What is an Enhanced Treatment Program or ETP? What is the history behind it and how is it used today?

In this episode, Dr. Andrew Cutler interviews Dr. Carolina Klein about how to diagnose and treat antisocial personality disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton

Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll

Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we take a look back at some of the incredible women in medicine we’ve had on the NEI Podcast over the years. We begin with reflecting on Episode 69: A Beacon of Hope in the Storm of Mental Illness: An Update on Suicide Awareness and Prevention with Dr. Christine Moutier. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention. To hear the full episode click on the link below:

https://neiglobal.libsyn.com/a-beacon-of-hope-in-the-storm-of-mental-illness-an-update-on-suicide-awareness-and-prevention-with-dr-christine-moutier

Next, we turn to Episode 77: Mental Health in the Muslim Community with Dr. Mona Masood. Dr Masood is a psychiatrist and she is on the Board of Directors at the Muslim Wellness Foundation. To listen to the full episode click on the link below:

https://neiglobal.libsyn.com/e77-mental-health-in-the-muslim-community-with-dr-mona-masood

We then return to our interview with Dr. Christina Girgis in Episode 79: Gender Disparities in the Mental Health Profession with Dr. Christina Girgis. Dr. Girgis is certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. To hear the complete episode click on the link below:

https://neiglobal.libsyn.com/e79-gender-disparities-in-the-mental-health-profession-with-dr-christina-girgis

Next, we reflect on Episode 82: Refreshing Perspectives on Recovery: September is National Recovery Month with Dr. Nzinga Harrison. Dr. Harrison is Board-Certified in both Adult General Psychiatry and Addiction Medicine and she is the Chief Medical Officer and Co-founder of Eleanor Health. To hear the full episode, click on the link below:

https://neiglobal.libsyn.com/e82

We then turn to Episode 101: Ooh Child, Things are Going to Get Easier: Managing Pediatric Anxiety with Dr. Krystal Lewis. Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). For the complete episode, click on the link below:

https://neiglobal.libsyn.com/e101-ooh-child-things-are-going-to-get-easier-managing-pediatric-anxiety-with-dr-krystal-lewis

Finally, we reflect on Episode 150: Blazing Trails to Breakdown Structural Racism and Improve Black Mental Health with Dr. Sarah Vinson. She is triple-board certified in adult, child & adolescent, and forensic psychiatry and the founder of the Lorio Psych Group. To listen to the complete episode, click on the link below:

https://neiglobal.libsyn.com/blazing-trails-to-breakdown-structural-racism-and-improve-black-mental-health

We hope you’ve enjoyed a look back at some of the most amazing women in medicine we’ve had on our show!

In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep

Learning Objectives: After completing this educational activity, you should be better able to:

• Utilize assessment tools in the diagnosis of insomnia
• Address challenges in the pharmacologic treatment of insomnia
• Implement evidence-based pharmacological treatments for insomnia

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

Credit Types. The following are being offered for this activity:

• Nurse Practitioner: ANCC contact hours
• Pharmacy: ACPE application-based contact hours
• Physician: ACCME AMA PRA Category 1 Credits ™
• Physician Assistant: AAPA Category 1 CME credits
• Psychology: APA CE credits
• Social Work: ASWB-ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.

InterviewerAndrew J. Cutler, MD  Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck

Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout.

Support: This activity is supported by an unrestricted educational grant from Eisai.

Released: August 31, 2022          CE credit expires: August 31, 2025

What is the difference between psychopathy and antisocial personality? What is known about gender differences when it comes to antisocial personality disorder?

In this episode, Dr. Andrew Cutler interviews Dr. James Knoll about how to diagnose and treat antisocial personality disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness.

Episodes to be released under this theme include:

Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton

Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll

Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we take a look back at Dr. Roger McIntyre’s presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders.

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

In today’s CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03

Learning Objectives: After completing this educational activity, you should be better able to:

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types. The following are being offered for this activity:

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.

InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options)

Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.

Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Released: July 27, 2022     CME/CE credit expires: July 27, 2025

In this episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs.

Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law.

With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness.

Episodes to be released under this theme include:

Part 1: Decriminalizing Mental Illness

Part 2: Managing the Unique Challenges of Correctional Psychiatry

Part 3: The Intensive Treatment Setting and Special Cases in Forensic Psychiatry

Subscribe to the NEI Podcast so that you don’t miss another episode!

Link to “Decriminalizing Mental Illness” by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

How did Fountain House come to be? What is the history behind it? What does it mean to be a Fountain House member? In this fascinating podcast, we hear from three experts who work with Fountain House to reduce stigma for people with serious mental illness, improve education, foster a community and provide resources for members of Fountain House to thrive and live fulfilling lives.

Fountain House is a national mental health nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people impacted by mental illness. Drawing on more than 200 community-based social rehabilitative programs inspired by Fountain House and known as clubhouses - to reflect an insistence on belonging and acceptance - in nearly 40 states and with more than 60,000 members, they are leading a national movement for the dignity and rights of people with serious mental illness.

Jeanie Tse, MD is the Senior Medical Director at Fountain House and an Associate Professor of Psychiatry at the NYU School of Medicine. She brings to Fountain House her expertise in integrated health care for people with serious mental illnesses, developed in the course of her work as the former Chief Medical Officer at the Institute for Community Living. She has a special interest in disrupting the impact of trauma on health outcomes, with an overarching aim to “bridge the gap” between academic psychiatry and the clinical challenges of under-resourced communities.

 Francesca Pernice, PhD is an associate professor in Educational Psychology and Director of Counseling Psychology at Wayne University's College of Education. Her areas of expertise include social and interpersonal relationships, clubhouse community recovery programs, recovery from serious mental illness, and research in mental health, and program evaluation. She instructs graduate courses in the area of adult psychopathology, ethics, and educational psychology. She serves as advisor for PhD students in the School Psychology PhD Concentration and Learning and Instructional Sciences PhD concentration within the department of Educational Psychology. Her areas of expertise include family psychoeducation about serious mental illness, and research of psychiatric rehabilitation programs known as Fountain House Clubhouses.

Cyrus Daniel Napolitano is a member of Fountain House who has served on their Board of Directors, the Council, a think-tank that focuses on innovation, training, education, research, public policy, advocacy, and technology. He is currently Co-Director of the Clubhouse New York Coalition that represents 14 clubhouses in NYC and in New Jersey. He is also working to foster the development of community-based mental health programs in low- to middle-income countries. 

Fountain House website: https://www.fountainhouse.org/

In this episode, Dr. Andrew Cutler interviews Dr. Tiffany Greenwood about the intersection of genetics, personality traits, temperament and cognitive traits in bipolar disorder and creativity. What is psychiatric genetics? What is known about dopamine’s role in creativity? Dr. Tiffany Greenwood address these questions and much more.

Dr. Greenwood received her B.S. in Molecular Biology and her Ph.D. in Biomedical Sciences from UC San Diego, with an emphasis in psychiatric genetics. She then augmented her molecular genetic background with postdoctoral training in applied statistical genetics and acquired supplemental training in clinical psychopathology through a Career Development Award from the National Institute of Mental Health (NIMH). She joined the Department of Psychiatry at UC San Diego in 2007 and is currently an Associate Professor. As the Director of the Laboratory for Psychiatric Spectrum Research, Dr. Greenwood’s research focuses on the use of dimensional and intermediate phenotypes, as well as clinical subphenotypes, to reduce clinical heterogeneity and refine the genetic signal. Such measures provide increased specificity, both within and across diagnostic categories, as well as a better reflection of the underlying biological processes. In this vein, Dr. Greenwood participates in a number of large-scale collaborations aimed at identifying genetic risk variants for psychiatric illness, including the Consortium on the Genetics of Schizophrenia (COGS), the Bipolar Genome Study (BiGS), and the Psychiatric Genomics Consortium (PGC). Her research in this area has been supported by a NARSAD Young Investigator Award for the development and utilization of a customized candidate gene array for schizophrenia and related phenotypes, as well as a K01 from the NIMH aimed at quantifying and interpreting the overlapping and unique aspects of bipolar disorder and schizophrenia. Dr. Greenwood has served as a Principal Investigator or Co-Investigator on a number of University and NIH-funded grants, including a current study exploring bipolar disorder as a dimensional phenotype existing at the extreme of normal population variation in positive traits, such as temperament, personality, creativity, and cognitive flexibility. Dr. Greenwood also recently received funding for a pilot project to implement a comprehensive screening and risk assessment program at UC San Diego. This project aims identify behavioral, environmental, and genetic factors associated with risk for mental health conditions, particularly mood disorders and suicide, and develop a risk prediction model to be used for early intervention.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder

Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko

Part 3: History of Creative Famous Individuals with Bipolar Disorder

Subscribe to the NEI Podcast, so that you don’t miss another episode!

How has your work in psychiatry consulting and education made a difference in fighting racism on both the individual and structural level? What is your book “Social (In)Justice and Mental Health” about? In this episode, Dr. Sarah Vinson shares her extensive experience and perspective on the intersection between child and adolescent psychiatry, forensics, and the fight for social justice in mental health.  

Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation in a wide variety of cases in criminal, civil and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation and psychopharmacology through her private practice, Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine. Just two years after joining the faculty she was honored as Psychiatry and Faculty of the Year in 2015. She is also Adjunct Faculty at Emory University School of Medicine. She has been elected and/or appointed to national and statewide office by her professional peers. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative.  She has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award.

Resources: https://drsarahvinson.com/

Link to “Social (In) Justice in Mental Health”: https://www.amazon.com/Social-Injustice-Mental-Health-Ruth/dp/1615373381/ref=sr_1_1?dchild=1&keywords=social%20injustice%20and%20mental%20health&qid=1608052484&sr=8-1

Learning Objectives: After completing this educational activity, you should be better able to:

• Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia
• Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia
• Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): knowledge-based contact hours  
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva 

Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee

Diana Perkins, MD, MPH

Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC 

Consultant/Advisor: Alkermes, Karuna

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout.

Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Released: May 27, 2022          CE credit expires: May 27, 2025

In this episode, Dr. Andrew Cutler interviews Mr. Marko Perko and Dr. Stephen Stahl about their newly released book “Tesla: His Tremendous and Troubled Life” and the intersection between Tesla’s genius, creativity, and bipolar disorder. How is your book unique from any book that’s been written on Tesla before? What is the main message that you’d like readers to take away from this book? In this episode Mr. Perko and Dr. Stahl address these questions and much more!

Marko Perko is a graduate of the University of Southern California. He has always had an insatiable thirst for knowledge of all types, and as such, he is highly regarded as a modern-day Renaissance man, author, historian, polymath, polemicist, and history communicator. He is the author of the critically acclaimed and wildly popular book “Did You Know That . . .?” He is also a novelist and the writer of an international bestselling knowledge-based board game, as well as the creator of the Cultural Enrichment Programs education series, and a software developer―Krypti.com.

Perko has written for and edited numerous publications, and he has worked as a columnist, speechwriter, composer, musician, lecturer, and playwright. He is a member of The Authors Guild; the Biographers International Organization; the American Society of Composers, Authors and Publishers; Broadcast Music, Inc.; the Institution of Engineering and Technology; the British Library; and the Organization of American Historians.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder

Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko

Part 3: History of Creative Famous Individuals with Bipolar Disorder

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Link to “Tesla: His Tremendous and Troubled Life”: https://www.amazon.com/Tesla-His-Tremendous-Troubled-Life-ebook/dp/B09QMPH6MG/ref=sr_1_1?crid=O0UAHNGC8Z0J&keywords=tesla+by+marko+perko&qid=1652729759&sprefix=tesla+by+marko+perko%2Caps%2C113&sr=8-1

Why are you so passionate about mental health care in the primary care setting? When did you first experience your own challenges with mental health? What is your advice for mental health professionals and medical professionals when it comes to prioritizing their own mental health? In this episode, Dr. Linda Gask answers these questions and much more about her own personal journey with mental health as a provider and a patient.

Dr. Linda Gask is a writer and a psychiatrist. She retired from being a consultant in the National Health Service and an academic at the University of Manchester some years ago. However she returned for a year during the coronavirus pandemic to work with the manchester-bereavement-service.org.uk/">Greater Manchester Bereavement Service and she is now Emerita Professor of Primary Care Psychiatry at the University of Manchester. She has been an advisor to the World Health Organization and was awarded the President’s Medal by the Royal College of Psychiatrists in 2017. She has experienced anxiety and depression throughout her adult life and she has written two memoirs called “The Other Side of Silence” and “Finding True North: The Healing Power of Place.” She was born in England, trained in Scotland where she currently resides.

Resources:

https://lindagask.com/

The Other Side of Silence: https://www.amazon.com/Other-Side-Silence-Psychiatrists-Depression-ebook/dp/B014I1F0QU/ref=sr_1_1?qid=1649898250&refinements=p_27%3ALinda+Gask&s=books&sr=1-1

Finding True North: The Healing Power of Place: https://www.amazon.com/Finding-True-North-Healing-Power/dp/B09VTJFDXV/ref=sr_1_5?qid=1649898250&refinements=p_27%3ALinda+Gask&s=books&sr=1-5

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation: ADHD, Female Hormones, and Menopause: The Little We Know from Research at the 2022 NEI Synapse.

In this episode, Carmen Kosciek discusses your most important questions from her presentation: Uploading Progress: Technology in Psychiatry at the 2022 NEI Synapse.

In this episode, Dr. Thomas Schwartz addresses your unanswered questions from his presentation: Too Much or Too Little: Sleep Issues and How to Treat Them at the 2022 NEI Synapse by Dr. Thomas Schwartz.

In this episode, Dr. Roger McIntyre addresses your most pressing questions from his presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania at the 2022 NEI Synapse.

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on creativity in bipolar disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder

Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko

Part 3: History of Creative Famous Individuals with Bipolar Disorder

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What led you to pursue a career in auditory neuroscience and what is the mission behind your laboratory, Brainvolts? What is the effect of bilingualism on Alzheimer’s disease? How can sound be used for the assessment of traumatic brain injury and other neurological conditions? In this episode, Dr. Nina Kraus addresses these questions and much more about the clinical applications for auditory neuroscience research. Her laboratory at Northwestern University, Brainvolts has discovered how to measure the biology of auditory processing with unprecedented precision. The implications of the research conducted there extends beyond the laboratory to schools, community centers, and clinics.

Nina Kraus, Ph.D. is a professor at Northwestern University who studies the biology of auditory learning. Through a series of innovative studies involving thousands of research participants from birth to age 90, her research has found that our lives in sound, for better (musicians, bilinguals) or worse (language disorders, concussion, aging, hearing loss), shape auditory processing. She continues to conduct parallel experiments in animal models to elucidate the mechanisms underlying these phenomena.

Never having accepted a lack of technology as a roadblock to scientific discovery, Kraus has invented new ways to measure the biology of sound processing in humans that provide precision and granularity in indexing brain function. With her technological innovations she is now pushing science beyond the traditional laboratory by conducting studies in schools, community centers, and clinics.

Using the principles of neuroscience to improve human communication, she advocates for best practices in education, health, and social policy. Dr. Kraus is the author of the book “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”.

Resources:

Link to “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”: https://www.amazon.com/Sound-Mind-Brain-Constructs-Meaningful/dp/0262045869#:~:text=Of%20Sound%20Mind%3A%20How%20Our,9780262045865%3A%20Amazon.com%3A%20Books

Link to Brainvolts: https://brainvolts.northwestern.edu/about-us/

Link to BEAMS hypothesis: 1.pdf">https://brainvolts.northwestern.edu/wp-content/uploads/2021/07/Kraus_BEAMS_2021-1.pdf

In this episode, Dr. Andrew Cutler interviews Dr. Rajnish Mago on best practices for early detection and screening for tardive dyskinesia.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD01

Learning Objectives: After completing this educational activity, you should be better able to:

• Conduct regular screenings for symptoms of tardive dyskinesia in patients with mood disorders and schizophrenia
• Employ evidence-based screening tools in the differential diagnosis of tardive dyskinesia, including the Abnormal Involuntary Movement Scale

 Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

 Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): knowledge-based contact hours  
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented.

Interviewer

Andrew J. Cutler, MDClinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee

Rajnish Mago, MD  Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY  Clinical Assistant Professor, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  Editor-in-Chief, Simple and Practical Medical Education  No financial relationships to disclose.

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout.

Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Released: March 23, 2022          CE credit expires: March 23, 2025

In what ways do we have the power to influence neuroplasticity? How would you define pathologic or dark neuroplasticity? Are there ways to enhance or preserve our circuits as a form of adaptive neuroplasticity?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on dark neuroplasticity.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale

Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti

Part 3: Good and Bad Neuroplasticity

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What was your personal experience with Match Day? What has your personal experience been like being transgender and how has this impacted your professional track when it comes to clinicians treating patients who are nonbinary or transgender?

In this podcast episode, Dr. Mulkey addresses these questions and more about psychiatry residency and Match Day.

Dr. Nat Mulkey, MD is a psychiatrist and first-year resident at the University of Vermont Medical Center. They graduated from Boston University School of Medicine, where they worked closely with faculty on LGBTQI+ curricula in undergraduate medical education and related initiatives. Their interests include child and adolescent psychiatry, LGBTQI+ mental health, pharmacology, addiction, and first break psychosis. Their hobbies are creative writing and trail running. 

Articles by Nat Mulkey, MD:

The Search for a Cause of Transness Is Misguided - Scientific American

training.org/misgendering-in-health-care-and-how-to-improve-20983">Misgendering in Medicine: How to Improve Care of Transgender and Gender Non-Binary Patients » in-Training, the online peer-reviewed publication for medical students

https://www.psychiatrictimes.com/view/mental-health-crisis-ground-level

https://www.aamc.org/news-insights/finding-my-community-gaymedtwitter

Resources for LGBTQ+ Clinicians and Caregivers:

Gender Spectrum Homepage - Gender Spectrum

Transgender Professional Association for Transgender Health | Trans Health by Trans People (tpathealth.org)

Education & Training - Fenway Health: Health Care Is A Right, Not A Privilege.

Resources for LGBTQ+ Patients: 

https://www.lgbtqiahealtheducation.org/resources/

https://www.uvmhealth.org/childrens-hospital/pediatric-specialties/transgender-youth-program/transgender-resources

https://www.uvm.edu/health/transhealth

Which unique factors of social media place it in a powerful position to influence people? How is marketing used as mass persuasion?

In this episode, Dr. Andrew Cutler interviews Dr. Donatella Marazziti on dark persuasion and social media.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale

Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti

Part 3: Good and Bad Neuroplasticity

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What was your experience like as co-chair of the Revision Subcommittee and DSM-5-TR editor? How was the impact of racism and discrimination on the diagnosis and manifestations of mental disorders addressed?

In this important and timely episode, Dr. Michael First addresses these questions and much more about the upcoming release of the DSM-5-TR in March 2022.

Dr. Michael B. First is a Professor of Clinical Psychiatry at Columbia University and a Research Psychiatrist at the Biometrics Department at the New York State Psychiatric Institute. He maintains a schematherapy and psychopharmacology practice in Manhattan. Dr. First is a nationally and internationally recognized expert on psychiatric diagnosis and assessment issues and has conducted expert forensic psychiatric evaluations in both civil and criminal matters, including the 2006 trial of the 9/11 terrorist Zacarias Moussaoui.

Dr. First is the Editorial and Coding Consultant for the DSM-5, the chief technical and editorial consultant on the World Health Organization's ICD-11 revision project and is an external consultant to the NIMH Research Domain Criteria project.

Dr. First has an undergraduate degree in Electrical Engineering and Computer Science from Princeton University, received a Masters in Computer Science and a Medical Degree from the University of Pittsburgh, completed his psychiatry residency at Columbia University, and also completed a fellowship in Biometrics Research under the direction of his mentor, Dr. Robert Spitzer.

He was the Editor of the DSM-IV-TR, the Editor of Text and Criteria for DSM-IV and the American Psychiatric Association (APA)'s Handbook on Psychiatric Measures. He has co-authored and co-edited a number of books, including A Research Agenda for DSM-V, the DSM-IV-TR Guidebook, the DSM-5 Handbook for Differential Diagnosis, and the Structured Clinical Interview for DSM-5 (SCID-5).

Notably, he is also the co-chair of the Revision Subcommittee and Editor of the DSM-5-TR

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch

Learning Objectives: After completing this educational activity, you should be better able to:

• Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics
• Follow evidence-based guidelines when switching antipsychotics

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. 

Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): knowledge-based contact hours  
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Stephen M. Stahl, MD, PhD, DSc (Hon.) 

Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA

Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK

Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA

Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion

Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor

Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex

Board Member: Genomind

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout.

Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

Released: January 26, 2022          CE credit expires: January 26, 2025

How did you come about writing “Dark Persuasion”? What exactly is brainwashing? What are the common features of torture and coercive persuasion?

In this episode, Dr. Andrew Cutler interviews Dr. Joel Dimsdale about his new book, “Dark Persuasion”.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale

Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti

Part 3: Good and Bad Neuroplasticity

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What exactly is seasonal affective disorder (SAD)? What are some of the most common symptoms?  In this episode, Dr. Jade Wu addresses these questions and much more about SAD.

Jade Wu, PhD, DBSM, is a Board-certified behavioral sleep medicine specialist and researcher at Duke University School of Medicine. Her current research focuses on treating sleep disorders in those with chronic illness.

She is a frequent guest on popular TV, radio and podcast shows like NPR and ABC, and her work is featured in publications like New York Times and Huffington Post. She formerly hosted the popular Savvy Psychologist podcast.

Dr. Wu’s mission is to spread the gift of sleep, so that people can be their healthiest, organizations can be their most innovative, and societies can sleep their way towards justice and healing.

In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.

 Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET

 Learning Objectives: After completing this educational activity, you should be better able to:

• Differentiate antipsychotic medications based on risk for metabolic side effects
• Monitor patients for metabolic side effects
• Implement management strategies to address metabolic side effects

 Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics

Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): application-based contact hours
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

 Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

 Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.

 Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Joseph F. Goldberg, MD  

Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY

Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion

Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion

Royalties: American Psychiatric Publishing, Cambridge University Press

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

 Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

 Released: December 22, 2021          CE credit expires: December 22, 2024

Can you explain how the same symptoms may cut across numerous psychiatric disorders and how the same treatment may be efficacious across psychiatric disorders? What areas in psychopharmacology remain the most challenging to treat and why do you think that is?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the future of psychopharmacology.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology?

Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

Part 3: The Future of Psychopharmacology

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health.

Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

What are some of the new FDA approvals for medications that happened this year? What did we learn about the association between ADHD and Alzheimer’s disease from a nationwide cohort study that was conducted? In this important and timely episode, Dr. Andrew Cutler addresses these questions and many more on the most interesting updates in psychopharmacology in 2021.

Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996.

Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Resources:

This Month in Psychopharmacology: https://www.neiglobal.com/Members/MonthInPsychopharmNew/tabid/508/Default.aspx

FDA Clears Technology to Aid in Concussion Diagnosis: https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/Default.aspx?topic=20527

International League Against Epilepsy Society (AES): https://www.ilae.org/

What was the inspiration behind creating the Fifth Edition video series? What are your best learning strategies for studying psychopharmacology?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the Fifth Edition Video Series and about the most effective learning strategies for psychopharmacology!

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology?

Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

Part 3: The Future of Psychopharmacology

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are you most excited about, when it comes to this year’s NEI Congress? What is one benefit that both live and virtual attendees will experience at the 2021 NEI Congress? In this episode, we get a sneak peek at what to expect from this highly anticipated event!

With the live and virtual simulcast formats, there are a lot of questions and A LOT of excitement! Whether you’ll be joining us in beautiful Colorado Springs or from the comfort of your own home, we have an unforgettable experience planned for you! Listen to this episode to learn more about what’s to come at the 2021 NEI Congress!

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD

Learning Objectives: After completing this educational activity, you should be better able to:

• Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes
• Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression
• Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Credit Types. The following are being offered for this activity:

• Nursing (ANCC): 1.0 contact hour
• Pharmacy (ACPE): 1.0 application-based contact hour
• Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™
• Physician Assistant (AAPA): 1.0 Category 1 CME credit
• Psychology (APA): 1.0 CE credit
• Social Work (ASWB-ACE): 1.0 ACE CE credit
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Roger S. McIntyre, MD, FRCPC

Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada

Grant/Research: CIHR/GACD/National Natural Science Foundation of China

Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Released: October 21, 2021          CE credit expires: October 21, 2024

What are some of the biggest changes that were made to the Fifth Edition and what were the reasons behind these changes? How are mood stabilizers redefined in the Fifth Edition?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about all the updates to the Fifth Edition of Stahl’s Essential Psychopharmacology and all the exciting reasons for those updates.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology?

Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

Part 3: The Future of Psychopharmacology

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What is unique about collaborative care, when it comes to mental health? Can you share some of the step-by -step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more!

Dr. Anna Ratzliff is a national expert on collaborative care and specifically, on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine.  She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions) and Director of the UW Integrated Care Training Program for residents and fellows.

Resources:

AIMS Center Website: http://aims.uw.edu/

Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide

APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia.

Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz

Learning Objectives: After completing this educational activity, you should be better able to:

• Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals
• Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes
• Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit.

Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee

Jonathan M. Meyer, MD

Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine

Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Released: September 23, 2021          CE credit expires: September 23, 2024

Why do you feel that when it comes to psychopharmacology, knowing how to really interpret the scientific literature is important for clinicians? Why is it important to know whether the clinical characteristics of the subjects resemble or differ from your own patients and to what extent?

 In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about why it is important to understand how to interpret the scientific literature and apply it to your clinical practice.

Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg

Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg

Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg

https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What are the most critical components that need to be addressed about social wellbeing when it comes to children returning to school? What signs might alert parents to their children feeling anxious about returning to school? In this timely and important interview. Dr. Manpreet Singh and Dr. Jeffrey Strawn answer these questions and much more!

To access the article that Dr. Singh refers to in this episode click here: to-school-fear-tip.html">https://www.nytimes.com/2021/08/20/well/family/back-to-school-fear-tip.html

Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.

Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

Dr. Jeffrey Strawn is Associate Professor in the Department of Pediatrics and in the Department of Psychiatry and Behavior Science at the University of Cincinnati, College of Medicine in Cincinnati, OH. Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents. 

In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders.

What is the difference between mediators and moderators, and how do they influence treatment response? Why is it so important, as clinicians to understand the distinction between moderators and mediators and to be aware of their influence on treatment outcomes in the literature?

 In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about how moderators and mediators influence clinical outcomes.

Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg

Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg

Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg

 https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Why is it so important that many Olympic athletes are speaking out about the importance of mental health, and how can people spread more awareness for mental health concerns in this vulnerable population? What challenges do you face regarding effectively treating mental health conditions in athletes? In this important and timely interview sports psychiatrist, Dr. Greg Mattingly addresses these questions and much more!

Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University. Dr. Mattingly has been a principal investigator in over 300 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for both the NFL and MLB. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family.

Resources: www.Midwestresearchgroup.com

In this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia.

Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1 

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe the challenges with traditional methods of treating schizophrenia
• Discuss the development of TAAR1 agonists as new class of psychotropic medication for the treatment of schizophrenia

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MDs and DOs: NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Astellas, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture 

Support: This activity is supported by an unrestricted educational grant from Sunovion Pharmaceuticals Inc.

Released: July 29, 2021 CME credit expires: July 29, 2024

How do you handle a patient who doesn’t want to talk about their suicidal thoughts? What tools and basic education strategies can we use for non-health-care professionals to highlight and prevent potential suicide/suicidal thoughts?  In this episode, Dr. Christine Moutier addressed your unanswered questions from the NEI Synapse Half Day: Before It’s Too Late: Strategies for Suicide Prevention.

Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions.

As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide.

Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the 1.pdf">Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry.

She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets.

You can follow Dr. Moutier on Twitter at @cmoutierMD.

For more information on the AFSP please visit: asfp.org

How does the therapeutic alliance influence treatment outcomes when it comes to treatment with placebo? What are some of the other patient characteristics that influence placebo responsivity? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn about why understanding more about placebo and nocebo effects is so important for your practice.

Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg

Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg

Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg

 https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What do we know about the world suicide rate and the national suicide rate? What are the differences and how might they be explained? How does the role of medications help or hinder suicide prevention? In this episode, Dr. Andrew Cutler interviews Dr. Christine Moutier and Dr. Stephen Stahl on their Suicide Prevention Handbook, where they address timely questions like these and so much more.

Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions.

As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide.

Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the 1.pdf">Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry.

She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets.

You can follow Dr. Moutier on Twitter at @cmoutierMD.

For more information on the AFSP please visit: asfp.org

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention.

Episodes to be released under this theme include:

Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre

Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre

Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the positive and negative consequences surrounding self-diagnosis programs for mental health? What can you say about the trend on TikTok to take L-tyrosine? It’s apparently been nicknamed the “natural Adderall”. What is wrong with this, or potentially dangerous about this? In this episode, Dr. Kojo Sarfo, discusses the positive and negative consequences of the mental health trends on TikTok and social media.

Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry.

Dr. Sarfo is dedicated to increasing awareness about mental health conditions and reducing the stigma that surrounds mental health on social media platforms, such as TikTok. His mission has been received with growing popularity, particularly in the adolescent/youth community- as he has over one million followers on TikTok. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students.

For more information on Dr. Sarfo: https://www.kojosarfo.com/

Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374

Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo

Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/

Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1

What are the most frequent comorbidities of schizophrenia? Is there any scientific reason to use any antipsychotic in twice-a-day dosing? In this episode, Dr. Leslie Citrome addresses these questions and more of your unanswered questions from the NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia in this special NEI Podcast Bonus episode!

Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.

Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.

Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time.

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention.

Episodes to be released under this theme include:

Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre

Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre

Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are some mental health challenges for Asian Americans today? Can you share your thoughts on the most recent acts of violence against Asian Americans and where it comes from? In this timely and important episode, we interview Dr. Rona Hu on mental health in the Asian American community.

Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in  minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching. Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology. Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998. Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders.

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

To register for Synapse Half-Days go to: https://www.neiglobal.com/Synapse/SynOverview/tabid/468/Default.aspx

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry.

To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention.

Episodes to be released under this theme include:

Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre

Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre

Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What has the research shown in terms of the relationship between THC and sleep and nightmares in patients with PTSD? What are your thoughts on the recent study by LaFrance et al. that claimed that PTSD symptoms were reduced by more than 50% after cannabis use? In this fascinating interview with Dr. Kari Franson, we discuss the evidence for and against the use of cannabis to treat PTSD.

Kari L. Franson PharmD, PhD, BCPP joined the University of Southern California in 2020 as the Associate Dean for Academic and Student Affairs and Professor of Clinical Pharmacy. Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands.

Dr. Franson is an educator with more than 25 years of experience. Throughout her career, she has focused on two areas: health professions education/workforce development and psychopharmacology. She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the US and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development.

Dr. Franson is also a US Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part 1: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part 2: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part 3: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the risk factors for pediatric anxiety, and how might those be altered by the pandemic? How can emotional intelligence and emotion regulation play a role in managing anxiety? What is self-efficacy, and why is it so important for managing pediatric anxiety? In this timely episode, we discuss how to manage pediatric anxiety with Dr. Krystal Lewis.

Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). She specializes in cognitive behavioral therapy (CBT) for treating pediatric anxiety, and her research has focused on identifying mechanisms underlying the effectiveness of CBT. Dr. Lewis has extensive clinical experience treating anxious children and adolescents. She is also an advocate for early intervention, prevention and evidence-based treatments. She is currently a member of the Board for the Anxiety and Depression Association of America and co-chairs the Child and Adolescent Anxiety Special Interest Group.

Resources

Research Involvement at the NIMH: www.nimh.nih.gov/research

Clinical Studies at the NIMH: clinicalstudies.info.nih.gov

Clinical Study on Pediatric Anxiety: mood-and-anxiety-research.shtml">https://www.nimh.nih.gov/research/research-conducted-at-nimh/join-a-study/trials/childrens-studies/pediatric-mood-and-anxiety-research.shtml Call: (301) 827-1340 /Email: kidswithworries@mail.nih.gov

Websites

My Mental Health: Do I Need Help? (NIMH)

5 Things You Should Know About Stress (NIMH)

COVID-19: Stress and Coping (CDC)

Anxiety and Depression Association of America: https://adaa.org/

Books for children/adolescents

Outsmarting Worry: The Older Kids’ Guide to Managing Anxiety:

https://www.amazon.com/Outsmarting-Worry-Older-Managing-Anxiety/dp/1785927825/ref=sr_1_1?dchild=1&keywords=outsmarting+worry&qid=1613673934&s=books&sr=1-1

Rewire Your Anxious Brain For Teens: https://www.amazon.com/Rewire-Your-Anxious-Brain-Teens/dp/1684033764/ref=sr_1_3?dchild=1&keywords=rewire+your+anxious+brain+for+teens&qid=1613674062&s=books&sr=1-3

https://www.amazon.com/Teen-Girls-Anxiety-Survival-Guide/dp/1684035848/ref=sr_1_3?dchild=1&keywords=the+teens+girls+anxiety+survival+guide&qid=1613677471&s=books&sr=1-3#customerReviews

Books for Parents :

https://www.amazon.com/Helping-Anxious-Child-Step-Step/dp/1572245751/ref=sr_1_1?dchild=1&keywords=helping+your+anxious+child&qid=1613674245&s=books&sr=1-1

https://www.amazon.com/You-Your-Anxious-Child-Worries/dp/1583334955/ref=sr_1_1?dchild=1&keywords=anne+marie+albano&qid=1613677395&s=books&sr=1-1

https://www.amazon.com/Anxious-Kids-Parents-Courageous-Independent/dp/0757317626/ref=sr_1_3?crid=VR7NZWB285S2&dchild=1&keywords=anxious+parents+anxious+kids&qid=1613677372&s=books&sprefix=anxious+parents+%2Cstripbooks%2C167&sr=1-3

What has research shown about the effectiveness of psychedelic or dissociative agents in the treatment of addiction? What is pharmacological extinction? What types of addictions have been researched, using this method as a treatment approach? In Part II of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more!

Don’t miss Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month.

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the greatest mental health disparities in this population? What has been particularly challenging for the transgender population during the COVID-19 pandemic? How can clinicians help recognize and treat the mental health needs of patients in the LGBTQ community, if they do not have advanced or specialized training for this population?

In this double-interview we had the opportunity to sit down with two experts who address these questions, and so much more!

Dr. Rhonda Schwindt is an Associate Professor and Director of the Psychiatric-Mental Health Nurse Practitioner Program at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LBGTQ health, trauma, and treatment-resistant psychiatric illnesses. Dr. Schwindt’s research is focused on reducing the disproportionate impact of substance use disorders among high risk populations. She has developed an innovative online module that prepares clinicians to engage in motivational interviewing and a web-based tool to assist busy clinicians with screening and brief intervention. Dr. Schwindt is currently conducting a study exploring the barriers to, and facilitators of, smoking cessation and treatment utilization among gender diverse people. She has received international recognition as an outstanding nurse educator as well as for clinical excellence in the care of persons living with mental illness. 

Dr. Stephen Forssell is the founder, director, and professor of the LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University. In addition, he has been an assistant professor in the Psychological and Brain Sciences Department at the George Washington University since 2002 where he teaches courses in sexuality and gender, health psychology, and social psychology. He is on the faculty of the GWU Medical Center School of Medicine and Health Sciences course in Human Sexuality and Clinical Medicine. Dr. Forssell’s expertise is in sexual orientation development, same-sex romantic relationships and parenting, HIV/AIDS risk behaviors, high risk sexual behavior interventions, adolescent and young adult romantic and sexual relationships, and health psychology. Dr. Forssell also designs program evaluations for the Human Services Administration, the Substance Abuse and Mental Health Services Administration, and for private agencies including the National Minority AIDS Council and the AIDS Alliance. 

Resources:

LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University: https://lgbt.columbian.gwu.edu/

National LGBTQIA Health Education Center:  https://www.lgbtqiahealtheducation.org/

Human Rights Campaign: https://www.hrc.org/

What types of psychotherapies are typically used in conjunction with these dissociative agents? How does psilocybin differ from ketamine for the treatment of mental health conditions? What are the risks, if any associated with this type of therapeutic approach? In Part I of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more!

Don’t miss Part II and Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month.

The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include:

Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy

Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process

Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories

Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic.  Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers and the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well. He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

We know that the COVID-19 pandemic has had a significant impact on mental health around the world. Can you share some findings with us on the effect of COVID-19 on mood disorders from the CLIMB study that was conducted this year? What were some of the new FDA approvals for medications that happened this year? In this episode, Dr, Cutler addresses these questions and so much more, as we take a look back at this year in psychopharmacology. Dr. Andrew J. Cutler is Chief Medical Officer at the Neuroscience Education Institute, and Clinical Professor in the Department of Psychiatry at SUNY Upstate Medical University, Syracuse, NY Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials. He has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences. Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis.

Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis

Learning Objectives: After completing this educational activity, you should be better able to:

• Describe the clinical presentation of psychosis in dementia
• Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee Laxman Bhagwan Bahroo, DO Associate Professor and Residency Program Director, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal, Neurocrine, Revance, Sunovion, US World Meds Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Neurocrine, Sunovion, UCB, US World Meds Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture 

Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals.

Released: December 14, 2020     CME credit expires: December 14, 2023

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population.

Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip

Learning Objectives: After completing this educational activity, you should be better able to:

• Discuss challenges to diagnosing bipolar disorder in the pediatric population (e.g. adolescents)
• Define the concept of “mixed features” according to different diagnostic criteria
• Improve the differential diagnosis of depression with mixed features (DMX) in children and adolescents
• Utilize evidence-based therapies in the treatment of pediatric patients presenting with DMX

Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.

Peer Review: The content was peer-reviewed by an MD specializing in pediatric psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Interviewee Neera Ghaziuddin, MD, MRCPsych Professor, Child and Adolescent Psychiatry Unit, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI No financial relationships to disclose.

Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found at https://nei.global/culture.

Support: This activity is supported by an unrestricted educational grant from Sunovion.

Released: December 3, 2020     CME credit expires: December 3, 2023

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress.

Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients improve their functionality and satisfaction in life. She considers a wide range of interventions including nutraceuticals, medication, exercise, yoga, psychotherapy, and sleep/relaxation training. Her specialties include: mood disorders, substance-use disorders, anxiety disorders, anger and irritability, behavioral addictions, co-occurring pain and opioid dependence.

Dr. Love is the co-author of When Crisis Strikes: 5 Steps to Heal Your Brain, Body, and Life from Chronic Stress. Stay up to date by following @dr_author_jennifer_love on Instagram.

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.

 Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD

 Learning Objectives: After completing this educational activity, you should be better able to:

• Identify the clinical presentation of tardive dyskinesia
• Implement treatment strategies for the management of tardive dyskinesia

 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

 Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.

 Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

 Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

 Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Jonathan M. Meyer, MD

Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine

Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

 Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.

 Released: November 19, 2020          CME credit expires: November19, 2023

What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more!

Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post.

Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives. 

My website: www.JadeWuPhD.com

Twitter: @JadeWuPhD

Resources can be found on her website under the "Resources" tab.

Join us for this important extended Q&A session with psychiatric nurse practitioner; Deb York, in which she answers your most pressing questions from her presentation on early life childhood adversity.

Join us for a fascinating extended Q&A with Dr. William Sauve’ where he addresses your unanswered questions from his presentation on the mental health consequences of COVID-19.

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.

In this exciting extended Q&A session, Dr. James Knoll addresses your unanswered questions from his presentation on Mass Shootings.

How do we know how much sleep we actually need? Are devices like the FitBit accurate at tracking what stage of sleep we’re in, according to heart rate? How does substance abuse contribute to nightmares? In this episode of the NEI Podcast, psychiatrist and sleep researcher, Dr. Jade Wu answers these questions and so much more! Learn about her cutting-edge research in Part 1 of this episode.

Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post.

Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives. 

My website: www.JadeWuPhD.com

Twitter: @JadeWuPhD

Resources can be found on her website under the "Resources" tab.

How are social media platforms being used for negativity and what can people do to protect their mental health on these platforms? How have you used Tiktok and other social media platforms to help remove the stigma associated with mental health conditions, and to make a positive impact in the adolescent population?

In this episode, we interview psychiatric nurse practitioner, Dr. Sarfo Kojo on how he is using social media to create a positive impact on mental health.

Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students.

Dr. Sarfo has over 328,000 followers on TikTok.

For more information on Dr. Sarfo: https://www.kojosarfo.com/

Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374

Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo

Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/

Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1

What is an ecological momentary assessment? How are ecological momentary interventions powerful and helpful in a clinical research setting? Learn more about how digital technology, smart phone applications, electronic surveys, and wearable devices can help in both the clinical research and the clinical treatment arena. In this fascinating interview with Dr. Katherine Houghton, she answers your most pressing questions about applying digital technology to capture real-world/real-time data, and to help patients at the most critical times.

Katherine Houghton, Ph.D. is fascinated by the intersection of technology and psychology. She is actively engaged in designing and testing systems to facilitate positive behavior change in a variety of populations. She co-founded ilumivu in 2009 (ilumivu.com) to provide software systems to researchers and clinicians to capture human data and deliver just-in-time interventions. Ilumivu's first software service was for parents of children with autism to track symptom change and treatment use in an online HIPAA compliant, sharable platform. Since then ilumivu has provided web, mobile and wearable systems to researchers and clinicians working with a wide range of populations including substance abuse, suicide, anxiety and depression. They are committed to finding innovative and effective ways to use everyday technology to improve the daily life experience of the millions of people who suffer with mental health issues. *Optional*Kat is also very engaged in local environmental activism bringing Community Rights and the Rights of Nature to the City of Asheville through a nonprofit she co-founded, Community Roots (cmroots.com). She also leads wilderness Rites of Passage ceremonies to help people through challenging times.

Resources:

Ilumivu website: https://ilumivu.com/

Ilumivu Twitter: https://twitter.com/ilumivuTweets

Kat's LinkedIn: https://www.linkedin.com/in/kathoughton/

Website to Kat's non-profit, Community Roots: https://www.cmroots.com/

Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.